Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

J B Chemicals and Pharmaceuticals Ltd

JBCHEPHARM:NSI

J B Chemicals and Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,960.30
  • Today's Change85.30 / 4.55%
  • Shares traded24.80k
  • 1 Year change+40.42%
  • Beta0.1676
Data delayed at least 15 minutes, as of Nov 01 2024 13:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

J.B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. The Company specializes in gastroenterology, hypertension and dermatology. It is also focused on other therapeutic categories like nephrology, respiratory, virology, diabetes, and nicotine replacement therapy (NRT). The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs). Its brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. It specializes in manufacturing of medicated and herbal lozenges. All its lozenges (herbal, medicated and soft-centered) can be made in sugar and sugar-free options. It has implemented osmotic-controlled release oral drug delivery system (OROS) technology. It maintains a direct presence in Russia and South Africa, along with distributor relationships in the United States and various markets throughout Asia, Africa, and Latin America.

  • Revenue in INR (TTM)35.92bn
  • Net income in INR5.87bn
  • Incorporated1976
  • Employees5.31k
  • Location
    J B Chemicals and Pharmaceuticals LtdCnergy It Park, Appa Saheb Marathe MargMUMBAI 400025IndiaIND
  • Phone+91 2 224395200
  • Fax+91 2 224395500
  • Websitehttps://jbpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Wockhardt Ltd28.93bn-3.43bn185.39bn2.39k------6.41-23.75-23.75199.60--------12,084,380.00---4.56---8.2958.6655.26-12.17-12.70--0.0764----5.55-4.7317.17---4.71--
Neuland Laboratories Ltd.16.35bn3.36bn187.40bn1.65k55.76--47.0311.46261.94261.941,274.50--------9,922,259.00--9.25--12.7153.3247.8120.5511.99--29.52--7.1330.8418.5183.5178.7617.8863.45
Astrazeneca Pharma India Ltd13.88bn958.59m190.62bn940.00198.86--171.8713.7438.3438.34555.18--------14,761,520.00--11.78--19.6248.5154.646.9110.27--121.25--25.6229.1712.2162.6624.29-10.46--
Concord Biotech Ltd10.38bn3.13bn191.48bn1.38k61.15--52.1818.4529.9329.9399.19--------7,537,496.00--------77.16--30.18----115.93----19.20--28.33------
Jubilant Pharmova Ltd69.20bn5.93bn191.94bn995.0032.413.2319.862.7737.3837.38436.41375.040.59341.758.1569,544,720.005.052.966.013.5568.5068.478.515.131.202.510.34224.736.70-5.95226.43-33.086.482.13
Alembic Pharmaceuticals Ltd63.04bn6.30bn221.89bn14.86k35.23--24.513.5232.0432.04320.63--------4,242,974.00--10.72--14.2573.1065.989.9912.47--12.52--28.2910.199.6280.071.05-15.5914.87
Pfizer Ltd22.38bn6.18bn233.22bn1.72k37.756.2234.3610.42135.06135.06489.19819.900.52881.8311.1613,004,360.0014.6014.2217.0517.7165.0061.3727.6124.054.3046.210.026782.67-9.551.05-11.645.1433.359.24
Natco Pharma Ltd.42.21bn16.37bn251.28bn4.02k15.35--13.785.9591.3791.37235.68--------10,510,210.00--12.33--14.2583.4073.0538.7725.16--91.13--18.9647.7213.8194.0916.59-4.7114.87
Laurus Labs Ltd50.53bn1.31bn264.86bn6.01k201.926.4048.585.242.432.4393.7076.700.6021.183.068,412,186.001.5510.132.5216.4753.4447.632.5812.830.58181.810.402313.00-16.5517.07-79.6811.3621.6821.67
Gland Pharma Ltd58.58bn7.22bn272.02bn4.22k37.67--24.884.6443.8343.83355.57--------13,890,770.00--13.23--14.5661.0055.5812.3322.92--34.66--7.2656.2922.61-1.1011.3224.02--
Emcure Pharmaceuticals Ltd-100.00bn-100.00bn272.13bn11.15k--------------------------7.14--13.93--59.29--7.81------0.0011.237.14-6.3621.35-5.93--
J B Chemicals and Pharmaceuticals Ltd35.92bn5.87bn304.58bn5.31k53.02--41.458.4836.9936.99226.16--------6,764,044.00--15.77--18.8966.2761.1816.3416.06--21.04--33.0810.6316.2234.8423.3640.1537.42
Suven Pharmaceuticals Ltd9.34bn2.40bn334.35bn1.05k138.89--112.9935.789.469.4636.75--------8,883,019.00--23.17--26.2056.5958.8525.7333.21--33.74--18.63-21.5622.71-26.9922.41-1.83--
Piramal Pharma Ltd87.04bn453.30m354.33bn6.72k787.954.4844.044.070.34070.340766.3659.910.57991.404.8812,954,040.000.302--0.428--63.69--0.5208--0.56037.490.3771--15.39--109.56------
Ajanta Pharma Ltd44.91bn8.75bn382.82bn7.84k44.0610.4137.838.5269.5569.55356.94294.360.97381.334.165,725,128.0018.9716.6123.2920.4775.7773.2219.4819.312.1349.880.008831.2012.4515.4138.8116.10-14.9710.76
IPCA Laboratories Ltd82.12bn5.77bn403.09bn17.34k69.88--42.484.9122.7422.74323.71--------4,737,502.00--10.33--13.5267.0859.166.8412.25--15.41--12.8623.3915.3516.134.2417.9021.67
Data as of Nov 01 2024. Currency figures normalised to J B Chemicals and Pharmaceuticals Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

17.48%Per cent of shares held by top holders
HolderShares% Held
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Sep 20244.67m3.01%
Axis Asset Management Co. Ltd.as of 30 Sep 20244.37m2.81%
Abrdn Asia Ltd.as of 24 Oct 20243.78m2.44%
The Vanguard Group, Inc.as of 02 Oct 20242.61m1.68%
Kotak Mahindra Asset Management Co. Ltd.as of 30 Sep 20242.60m1.68%
Norges Bank Investment Managementas of 30 Sep 20242.47m1.59%
Canara Robeco Asset Management Co. Ltd.as of 30 Sep 20241.96m1.26%
Invesco Asset Management (India) Pvt Ltd.as of 30 Sep 20241.86m1.20%
Franklin Templeton Asset Management (India) Pvt Ltd.as of 30 Sep 20241.45m0.93%
Capital Research & Management Co. (World Investors)as of 30 Sep 20241.38m0.89%
More ▼
Data from 30 Jun 2024 - 24 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.